Overview
Sweden-based healthcare and diagnostics provider's Q1 revenue rose 8% yr/yr to EUR 624.2 mln
Q1 operating profit grew 30% and net profit rose 10% yr/yr
Company cites strong organic growth and improved pricing, with India showing double-digit gains
Outlook
Medicover expects to continue growth and margin expansion in line with mid-term targets
Result Drivers
INDIA GROWTH - Strong double-digit revenue growth in India driven by new hospital openings and doctor recruitment
SYNLAB ACQUISITIONS - Acquired SYNLAB businesses supported improved profitability and volume growth in Diagnostic Services
Company press release: ID:nMFN4pHnZB
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 624.20 mln
Q1 Basic EPS
EUR 0.15
Q1 EBIT
EUR 46.70 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Medicover AB is SEK277.50, about 43.8% above its April 28 closing price of SEK193.00
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 28 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
